Symbol List Views
Stock Details
CHARTS
COMPANY NEWS
STOCK ANALYSIS
FUNDAMENTALS
HOLDINGS
Edit Symbol List
Symbol Lookup
TEVA: Stock Quote & Summary Data
1.09%
| Last Sale | |
| Change Net / % |
|
| Best Bid / Ask | |
| 1y Target Est: | N/A |
| Today's High / Low | / |
| Share Volume | |
| 50 Day Avg. Daily Volume | 5,217,292 |
| Previous Close | $ 56.92 |
| 52 Wk High / Low | $ 59.62 / $ 41.70 |
| Shares Outstanding | 919,000,000 |
| Market Value | $ 52,879,260,000 |
| P/E Ratio | 18.04 |
| Forward P/E (1yr) | N/A |
| Earnings Per Share | $ 3.19 |
| Annualized Dividend | $ 0.5047 |
| Ex Dividend Date | Nov. 6, 2009 |
| Dividend Payment Date | Dec. 4, 2009 |
| Current Yield | 0.89 % |
| Beta | 0.57 |
| NASDAQ Official Open Price: | $ 57.36 |
| Date of NASDAQ Official Open Price: | Feb. 9, 2010 |
| NASDAQ Official Close Price: | $ 56.92 |
| Date of NASDAQ Official Close Price: | Feb. 8, 2010 |
Intraday Chart |
| 5d | 1m | 6m | 12m | More Charting |
Have a Question About TEVA?
Ask your question about about Teva Pharmaceutical Industries Limited (TEVA) by typing it in the box below. You'll get direct responses from other members of the NASDAQ Answers community!
Hot Topics in NASDAQ Answers
The most popular questions & answers in the
NASDAQ Answers Community:
Company Description (as filed with the SEC)
Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, produces and markets generic drugs covering all major treatment categories. It is the leading generic drug company in the world, as well as in the United States, in terms of total and new prescriptions. Teva also has a significant and growing innovative pharmaceutical business, whose principal products are Copaxone® for multiple sclerosis and Azilect ® for Parkinson’s disease, as well as an expanding proprietary specialty pharmaceutical business, which consists primarily of respiratory products. Teva’s active pharmaceutical ingredient (“API”) business sells to third-party manufacturers and provides significant vertical integration to Teva’s own pharmaceutical production. Teva’s global operations are conducted in North America, Europe, Latin America, Asia and Israel. ... More ...
Links to all Teva Pharmaceutical Industries Limited (TEVA) Pages
Stock Analysis
Fundamentals
Holdings/Ownership
Company News for TEVA |
||
|
UPDATE: Ratiopharm Shortlist Expected Early Next Week - Sources - Dow Jones Business News 02/09/2010 12:18PM |
||
|
UPDATE: Biogen 4Q Profit Up 48%; Offers Bright 2010 Forecast - Dow Jones Business News 02/09/2010 11:35AM |
||
|
The New Danger for Foreign Investors? - The Motley Fool 02/09/2010 11:17AM |
||
|
Ratiopharm Shortlist Expected Early Next Week - Sources - Dow Jones Business News 02/09/2010 11:14AM |
||
|
BioSante Pharmaceuticals Appoints Jeffrey W. Winkelman, Ph.D., J.D., Vice President, Oncology Programs - Business Wire 02/09/2010 8:00AM |
Consensus Recommendation |
|
Analyst Info |
|
| Annual EPS Est: | N/A |
| Quarterly EPS Est: | N/A |
| PEG Ratio: | N/A |
| Mean Recommendation: View Summary/View All |
N/A |
